msc

Orcinol glucoside (Sakakin) (OG), an active constituent isolated from the rhizomes of Curculigo orchioides Gaertn, shows potent antioxidative and anxiolytic activities without sedative effects.

MSC2360844 is a potent, orally active and selective inhibitor of PI3Kδ(IC50 of 145 nM).

MSC1094308 is a reversible, non-ATP-competitive alterative inhibitor targeting type II AAA ATPase (VCP/p97) and type I AAA ATPase (VPS4B), which affects the intracellular protein degradation process by binding to a specific hotspot region of p97 and inhibiting D2 ATPase activity.

MSC 2032964A is a potent selective ASK1 inhibitor (IC50 = 93 nM) that is oral bioavailable and brain permeable. It inhibited neuroinflammation in mouse EAE models and blocked LPS-induced phosphorylation of ASK1 and p38 in cultured mouse astrocytes.

MSC-4381 (MCT4-IN-1) is an orally available and selectively modeled highly potent inhibitor of monocarboxylic acid transporter protein 4 (MCT4/SLC16A3) with potential anticancer and antitumor activity for the study of osteosarcoma.

MSC2360844 hemifumarate is a highly potent and orally active compound that acts as a selective inhibitor of PI3Kδ, with an IC50 value of 145 nM. This compound exhibits exceptional selectivity against a comprehensive panel of 278 additional kinases.

MSC2504877 is an inhibitor of tankyrase and enhances the effects of clinical CDK4/6 inhibitors. MSC2504877 suppresses the upregulation of Cyclin D2 and Cyclin E2 caused by palbociclib and enhances the suppression of phospho-Rb.

MSC-4106, an orally active and potent YAP/TAZ-TEAD inhibitor, disrupts TEAD1 and TEAD3 auto-palmitoylation and demonstrates significant efficacy in the NCI-H226 tumor xenograft model [1].

MSC-1186 is a potent and highly selective inhibitor targeting the pan-SRPK family, including SRPK1, SRPK2, and SRPK3, with IC 50 values of 2.7 nM, 81 nM, and 0.6 nM, respectively. Its specificity and effectiveness make it suitable for cancer research applications.

MSC-1 (Anti-LIF Antibody) is a humanized anti-leukemia inhibitory factor (LIF) monoclonal antibody that acquires anti-tumor and pro-inflammatory functions in a homozygous colon cancer mouse model and can be used to study advanced solid tumors.

MSC2530818 is an effective, selective and orally available CDK8 inhibitor (IC50: 2.6 nM).

MSC-5046 is a selective inhibitor of TEAD1.

MSC-1254 is a reversible, selective, and covalent inhibitor of TEAD1, primarily utilized in cancer research.

MSC778 is a selective and orally active inhibitor of flap endonuclease 1 (FEN1), with an IC50 of 3 nM and a KD of 2.9 nM. It exhibits 145-fold, 516-fold, and 65-fold selectivity over EXO1, GEN1, and XPG, respectively. MSC778 selectively targets BRCA2-deficient cells and enhances the tumor-stalling activity of Niraparib in BRCA2 KO DLD-1 mouse xenografts. It is applicable in colorectal cancer research.

Tepotinib (EMD-1214063) is a c-MET tyrosine kinase inhibitor (IC50=3 nM) that is selective, orally active, and ATP-competitive. Tepotinib has antitumor effect and is used in the treatment of non-small cell lung cancer.

Thiorphan disulfide is an impurity of Racecadotril -- an antidiarrheal and enkephalinase inhibitor that reduces the amount of water and electrolytes absorbed into the intestine.

NB-533 is a macrocyclic peptidic BACE-1 inhibitor.

Se-Methylselenocysteine (Se-MSC) is a potent chemopreventive agent in many test systems and has been shown to inhibit tumor promotion and induce apoptosis.

Jimscaline (compound R-(-)2) is a 5-HT2A agonist and a mescaline analogue, used in neuroscience research.

Deferoxamine Mesylate (DFOM) is an iron chelator and ferroptosis inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and induces apoptosis.

Gamithromycin (ML-1709460) is a macrolide compound with antibacterial activity.

BRD9876 is a selective inhibitor of MM1S growth.

Evobrutinib(M2951) , also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton's tyrosine kinase (BTK), which is important in the development and functioning of various immune cells including B -lymphocytes and macrophages. PreClinical research suggests it may be therapeutically useful in certain autoimmune diseases.

Vimseltinib (DCC-3014) is a dual inhibitor targeting c-FMS (CSF-IR) and c-Kit with IC50 values of less than 0.01 μM and 0.1-1 μM, respectively.